The 2007 American College of Infectious Diseases/American Thoracic Society Guidelines for the Diagnosis and Treatment of Community-Acquired Pneumonia in Adults recommends influenza vaccination and Streptococcus pneumoniae vaccine indications (Strongly recommended, Level of Evidence I); 2. For people aged 5-49 years without chronic underlying diseases such as immunodeficiency, asthma, or chronic medical conditions, intranasal administration of live attenuated vaccine is an option. (Strongly recommended, Level of Evidence I); 3. Health care workers working in inpatient services, outpatient clinics, and long-term care facilities should be routinely vaccinated annually with influenza vaccine. (Strongly recommended, Level of Evidence I); 4. Persons recommended for polyvalent Streptococcus pneumoniae vaccination according to the Immunization Committee Advisory Group guidelines include those over 65 years of age and those selected as being at high risk for other diseases: (Strongly recommended, Level of Evidence II); 5. All hospitalized patients need to be evaluated for immunization status, especially those with comorbid medical conditions. (Moderate recommendation, Level of Evidence III); 6. Vaccination can be given at discharge or during outpatient care (Moderate recommendation, Level of Evidence III); 7. Influenza vaccine should be given to patients at discharge or during outpatient care in the fall and winter (Strong recommendation, Level of Evidence III); 8. Smoking cessation should be a goal for patients hospitalized for CAP. （Smokers who do not want to quit should also be vaccinated against Streptococcus pneumoniae and influenza (mildly recommended, Level of Evidence III); 10. Cases of pneumonia of public health concern should be reported immediately to the state or local health agency. (Strongly recommended, Level of Evidence III); 11. Hygienic management of respiratory illnesses, including hand washing and masks or substitutes for coughing patients, should be implemented in outpatient clinics and public places as a measure to reduce the spread of respiratory illnesses. (Strongly recommended, Level of Evidence III); Caution: 1. Avoid use in: asthma, airway hyperresponsiveness disease, or other chronic diseases of the cardiopulmonary system; patients with comorbid other underlying medical conditions, including diabetes, renal failure, and hemoglobinopathies; immunodeficient patients or patients receiving immunosuppressive therapy; children or adolescents receiving salicylates with a history of Guillain -Barre syndrome history, and pregnant women. 2. Those who are smoking are recommended for vaccination by the Pneumonia Guidelines Committee, but are not an indication for vaccination as currently recommended by the Advisory Group of Immunization Commissioners.